ALFA FinderBSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,860.00
- Market cap
- ₹4,46,276 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 40.7×Sector 43.0×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Price Movement Clarification
Sun Pharma said a 30 October 2026 news report concerned August 2026 developments, not new events. It confirmed no undisclosed material information explains the share price movement.
Sun Pharmaceutical Industries Annual General Meeting
Sun Pharma's postal ballot passed all seven special resolutions, including ESOP 2026 approval and borrowing and security limits. No monetary transaction is stated.
Sun Pharmaceutical Industries Earnings Call Transcript: Key Takeaways
Sun Pharma delivered resilient double-digit revenue growth despite U.S. specialty headwinds, masking underlying margin pressure from lower Lenalidomide sales.
Sun Pharmaceutical Industries Other Announcement
Sun Pharma's board appointed Deloitte as Statutory Auditors under mandatory rotation, effective from the FY 2026-27 AGM. This follows SRBC & CO's second five-year term completion.
Sun Pharmaceutical Industries Q2 FY27 Results: Net Profit ₹1,995 Cr, Down 36.2% YoY
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹16,199 Cr (+11.9% YoY) and net profit of ₹1,995 Cr (-36.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,995 Cr · -36.2% YoY
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Other promoter reclassification announcements
All →Baba Arts Promoter Reclassification
Baba Arts' board noted promoters Gordhan and Rahul Tanwani's request to reclassify as public shareholders. Company Secretary Naishadh Mankad resigned and Shilpi Shukla was appointed.
Vaxtex Cotfab Promoter Reclassification
Vaxtex Cotfab received NSE approval to reclassify Bharti Kailash Gupta, holding 0.40%, from promoter group to public. The change took effect on 5 November 2026.
Shri Gang Industries and Allied Products Promoter Reclassification
Shri Gang Industries received BSE no-objection for reclassifying four Gupta family members from promoter to public category under Regulation 31A. Shareholder approval is still required, and no monetary value is involved.
Olympic Management & Financial Services Promoter Reclassification
Olympic Management & Financial Services received BSE no-objection to reclassify Excel Paints Private Limited from promoter to public category under Regulation 31A. No shares or money changed hands.
EMA India Promoter Reclassification
EMA India submitted minutes of a postal ballot completed on 8 October 2026. Members approved reclassifying 38,000 shares (3.78%) from promoter to public category under Regulation 31A.
GSPL Transmission Promoter Reclassification
GSPL Transmission's board approved GSEG's request to reclassify from Promoter to Public shareholder, subject to Regulation 31A approvals. No shareholder approval is needed as GSEG holds under 1% of voting rights.